Conjugated estrogens+bazedoxifene therapy

Conjugated estrogens in combination with bazedoxifene (a selective estrogen receptor modulator) can be used in postmenopausal individuals as an alternative to continuous combined MHT.

Conjugated estrogens+bazedoxifene improves bone mineral density at the hip and spine but is less effective than the combination of conjugated estrogens and medroxyprogesterone. It does not increase breast density; however, the long-term risks of breast cancer are unclear. Effects on risk of venous thromboembolism, coronary heart disease and stroke are unclear, because trials were not powered to detect differences.

In postmenopausal individuals, use:

Metabolism of bazedoxifene is increased by some drugs (including rifampicin, phenobarbital, carbamazepine and phenytoin¹), resulting in inadequate endometrial protection; seek specialist advice if no alternative form of MHT is suitable.